Literature DB >> 8165859

The pulmonary immune response of Balb/c mice vaccinated with the fusion protein of respiratory syncytial virus.

G E Hancock1, D J Hahn, D J Speelman, S W Hildreth, S Pillai, K McQueen.   

Abstract

We have investigated the efficacy of vaccination with the purified fusion (F) protein of respiratory syncytial virus (RSV) on aluminium hydroxide adjuvant in Balb/c mice. The purpose of the study was to define the role of the local pulmonary mononuclear cell (PMC) infiltrate in the clearance of virus from the lower respiratory tract. Balb/c mice immunized with F protein were able to inhibit the replication of virus in the lungs as early as 4 days after intranasal challenge. In contrast, unimmunized mice required 8 days. Examination of humoral immune mechanisms demonstrated that vaccination with the purified protein induced moderate titres of serum neutralizing antibody. In addition, immunization induced low to moderate levels of antigen-dependent killer cell activity. To examine the immunological events responsible for virus clearance in vivo, PMC infiltrates were isolated after virus challenge and tested directly for protective capacity. After virus challenge, the F protein-immune mice were able to recall the cytolytic cells to the pulmonary tissues. The results further suggested that the local antigen-dependent killer activity was mediated by cytolytic T cells of the CD8 phenotype. Adoptive transfer studies were also conducted to identify further the role the PMC infiltrate had in protective immunity. Adoptive transfer of F protein-educated PMC into naive syngeneic recipients suggested that the pulmonary infiltrates contained the cellular constituents necessary for protective immunity. Both humoral and cellular immune elements were present.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8165859     DOI: 10.1016/0264-410x(94)90204-6

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus.

Authors:  G E Hancock; D J Speelman; K Heers; E Bortell; J Smith; C Cosco
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

2.  Modulation of protective immunity, eosinophilia, and cytokine responses by selective mutagenesis of a recombinant G protein vaccine against respiratory syncytial virus.

Authors:  Yan Huang; Robert Anderson
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

3.  A recombinant anchorless respiratory syncytial virus (RSV) fusion (F) protein/monophosphoryl lipid A (MPL) vaccine protects against RSV-induced replication and lung pathology.

Authors:  Jorge C G Blanco; Marina S Boukhvalova; Lioubov M Pletneva; Kari Ann Shirey; Stefanie N Vogel
Journal:  Vaccine       Date:  2013-11-16       Impact factor: 3.641

4.  Formulation with CpG oligodeoxynucleotides prevents induction of pulmonary immunopathology following priming with formalin-inactivated or commercial killed bovine respiratory syncytial virus vaccine.

Authors:  M Oumouna; J W Mapletoft; B C Karvonen; L A Babiuk; S van Drunen Littel-van den Hurk
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

5.  Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology.

Authors:  Matthew R Murawski; Lori W McGinnes; Robert W Finberg; Evelyn A Kurt-Jones; Michael J Massare; Gale Smith; Penny M Heaton; Armando E Fraire; Trudy G Morrison
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

6.  Recombinant respiratory syncytial viruses lacking the C-terminal third of the attachment (G) protein are immunogenic and attenuated in vivo and in vitro.

Authors:  Matthew B Elliott; Karin S Pryharski; Qingzhong Yu; Christopher L Parks; Todd S Laughlin; C Kanta Gupta; Robert A Lerch; Valerie B Randolph; Natisha A LaPierre; Kristen M Heers Dack; Gerald E Hancock
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

7.  An adjuvanted respiratory syncytial virus fusion protein induces protection in aged BALB/c mice.

Authors:  Anu Cherukuri; Kate L Stokes; Kathryn Patton; Howard Kuo; Kaori Sakamoto; Stacie Lambert; Elizabeth Stillman; Martin L Moore; Sujin Lee
Journal:  Immun Ageing       Date:  2012-10-02       Impact factor: 6.400

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.